Inhibiting TKT or PKM2 could disrupt the metabolic adaptations that sustain RCC progression and chemoresistance, and a dual-targeting approach against TKT and PKM2 may offer a more effective therapeutic strategy for RCC. The gene discussed is PKM; the disease is renal cell carcinoma.